The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development

The antibiotic pipeline is thin and lacks diversity, particularly for agents targeting Gram‐negative pathogens. The reasons for our anemic global development pipeline are often summarized as (i) discovery of new antibiotics is difficult, (ii) clinical development of new antibiotics is difficult, and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2014-08, Vol.96 (2), p.166-168
Main Authors: Tomayko, J F, Rex, J H, Tenero, D M, Goldberger, M, Eisenstein, B I
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - pharmacokinetics
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Clinical Trials as Topic - trends
Drug Discovery - legislation & jurisprudence
Drug Discovery - trends
Drug Resistance, Multiple, Bacterial - drug effects
Drug Resistance, Multiple, Bacterial - physiology
Humans
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antibiotic pipeline is thin and lacks diversity, particularly for agents targeting Gram‐negative pathogens. The reasons for our anemic global development pipeline are often summarized as (i) discovery of new antibiotics is difficult, (ii) clinical development of new antibiotics is difficult, and (iii) the economics for new antibiotics are unfavorable for the developer. Here, we review recent efforts directed at the second of these challenges. Clinical Pharmacology & Therapeutics (2014); 96 2, 166–168. doi:10.1038/clpt.2014.107
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2014.107